X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24631) 24631
Publication (1817) 1817
Newsletter (1358) 1358
Book Review (297) 297
Newspaper Article (258) 258
Magazine Article (175) 175
Book Chapter (103) 103
Transcript (45) 45
Trade Publication Article (36) 36
Conference Proceeding (35) 35
Dissertation (26) 26
Book / eBook (10) 10
Web Resource (7) 7
Data Set (6) 6
Reference (6) 6
Presentation (3) 3
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19005) 19005
warfarin (16550) 16550
index medicus (10594) 10594
male (10003) 10003
female (9932) 9932
warfarin - therapeutic use (8803) 8803
anticoagulants - therapeutic use (8565) 8565
aged (7782) 7782
middle aged (6877) 6877
anticoagulants (6179) 6179
atrial fibrillation (5333) 5333
stroke (4628) 4628
risk factors (4436) 4436
anticoagulants - adverse effects (4350) 4350
adult (4174) 4174
anticoagulants - administration & dosage (3898) 3898
cardiac & cardiovascular systems (3724) 3724
warfarin - adverse effects (3662) 3662
aged, 80 and over (3447) 3447
anticoagulation (3291) 3291
atrial fibrillation - drug therapy (3291) 3291
warfarin - administration & dosage (3245) 3245
prevention (3127) 3127
treatment outcome (3003) 3003
peripheral vascular disease (2901) 2901
therapy (2887) 2887
hematology (2886) 2886
pharmacology & pharmacy (2833) 2833
medicine, general & internal (2791) 2791
risk (2782) 2782
international normalized ratio (2708) 2708
thromboembolism (2632) 2632
atrial fibrillation - complications (2589) 2589
stroke - prevention & control (2561) 2561
administration, oral (2497) 2497
dabigatran (2494) 2494
management (2464) 2464
retrospective studies (2306) 2306
hemorrhage - chemically induced (2261) 2261
care and treatment (2227) 2227
aspirin (2196) 2196
atrial-fibrillation (2104) 2104
thrombosis (2030) 2030
research (2023) 2023
analysis (1953) 1953
drug therapy (1842) 1842
rivaroxaban (1755) 1755
abridged index medicus (1707) 1707
surgery (1699) 1699
time factors (1632) 1632
stroke - etiology (1574) 1574
thromboembolism - prevention & control (1574) 1574
hemorrhage (1566) 1566
mortality (1561) 1561
medicine & public health (1517) 1517
aspirin - therapeutic use (1516) 1516
venous thromboembolism (1500) 1500
health aspects (1465) 1465
patients (1457) 1457
heparin - therapeutic use (1439) 1439
stroke prevention (1418) 1418
prospective studies (1394) 1394
dosage and administration (1391) 1391
follow-up studies (1372) 1372
cardiac arrhythmia (1344) 1344
medical research (1326) 1326
drug interactions (1319) 1319
bleeding (1294) 1294
antithrombotic therapy (1288) 1288
risk assessment (1268) 1268
animals (1259) 1259
cardiology (1194) 1194
safety (1180) 1180
medicine, experimental (1177) 1177
apixaban (1162) 1162
platelet aggregation inhibitors - therapeutic use (1127) 1127
usage (1081) 1081
oral anticoagulation (1046) 1046
dose-response relationship, drug (1039) 1039
oral anticoagulants (1039) 1039
risk-factors (1038) 1038
complications (1024) 1024
adolescent (1008) 1008
internal medicine (1004) 1004
clinical neurology (991) 991
fibrinolytic agents - therapeutic use (989) 989
complications and side effects (979) 979
vitamin k - antagonists & inhibitors (978) 978
drug therapy, combination (972) 972
warfarin - pharmacology (966) 966
prothrombin time (960) 960
heparin (953) 953
incidence (947) 947
fibrillation (911) 911
molecular-weight heparin (903) 903
thrombin (901) 901
metaanalysis (895) 895
cardiovascular (888) 888
pharmacogenetics (886) 886
blood coagulation - drug effects (885) 885
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (25465) 25465
Japanese (223) 223
French (177) 177
Spanish (144) 144
German (138) 138
Russian (115) 115
Italian (52) 52
Chinese (51) 51
Portuguese (29) 29
Swedish (27) 27
Turkish (22) 22
Norwegian (21) 21
Czech (19) 19
Polish (19) 19
Finnish (17) 17
Danish (16) 16
Hungarian (15) 15
Korean (11) 11
Hebrew (9) 9
Dutch (5) 5
Afrikaans (3) 3
Croatian (3) 3
Persian (3) 3
Slovak (3) 3
Serbian (2) 2
Ukrainian (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA Neurology, ISSN 2168-6149, 12/2018, Volume 75, Issue 12, pp. 1511 - 1518
IMPORTANCE Non-vitamin K antagonist oral anticoagulants (NOACs) might be an attractive choice for stroke prevention in people without atrial fibrillation who... 
DABIGATRAN | SUBTYPES | RIVAROXABAN | EMBOLIC STROKE | LEFT ATRIAL ABNORMALITY | APIXABAN | CLINICAL NEUROLOGY | Heart | Anticoagulants | Medical research | Aspirin | Stroke | Warfarin | Clinical trials | Acetylsalicylic acid | Hemorrhage | Risk factors | Bleeding | Randomization | Fibrillation | Data collection | Drug therapy | Vitamin K | Online First | Original Investigation | Research
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 06/2012, Volume 107, Issue 6, pp. 1053 - 1065
Journal Article
Circulation, ISSN 0009-7322, 07/2007, Volume 116, Issue 5, pp. 552 - 560
fondaparinux | CARDIAC & CARDIOVASCULAR SYSTEMS | bivalirudin | STROKE PREVENTION | myocardial infarction | INITIAL TREATMENT | heparin | ST-ELEVATION | PERCUTANEOUS CORONARY INTERVENTION | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | anticoagulants | mortality | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | enoxaparin | NONVALVULAR ATRIAL-FIBRILLATION | Fibrinolytic Agents - classification | Recombinant Proteins - therapeutic use | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Benzylamines - adverse effects | Factor Xa Inhibitors | Anticoagulants - classification | Humans | Thrombin - antagonists & inhibitors | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Rivaroxaban | Pyridines - adverse effects | Angina, Unstable - drug therapy | Prothrombin - antagonists & inhibitors | Hirudins - pharmacokinetics | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Polysaccharides - therapeutic use | Azetidines - adverse effects | Peptide Fragments - pharmacokinetics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Forecasting | Azetidines - therapeutic use | Brain Ischemia - drug therapy | Peptide Fragments - therapeutic use | Benzylamines - pharmacokinetics | Hemorrhage - chemically induced | Heparin - therapeutic use | Recombinant Proteins - pharmacokinetics | Dabigatran | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - therapeutic use | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Thrombophilia - drug therapy | Pyridines - therapeutic use | Azetidines - pharmacokinetics | Clinical Trials as Topic | Coumarins - therapeutic use | Polysaccharides - pharmacology | Thiophenes - pharmacokinetics | Myocardial Infarction - drug therapy | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Benzylamines - therapeutic use | Physiological aspects | Usage | Warfarin | Heparin
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2015, Volume 128, Issue 12, pp. 1300 - 1305.e2
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
Mortality and morbidity in acute coronary syndromes (ACSs), caused principally by plaque erosion or rupture leading to thrombus formation and myocardial... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 17, pp. 1486 - 1494
Background Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF). Methods and... 
Heart failure | Stroke | Sinus rhythm | Atrial fibrillation | Risk factors | Ventricular ejection fraction | heart failure | risk factors | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR SYSTOLIC FUNCTION | RANDOMIZED-TRIAL | NATRIURETIC PEPTIDE | stroke | ASPIRIN | atrial fibrillation | CONVERTING-ENZYME INHIBITORS | THERAPY | WARFARIN | EJECTION FRACTION | ventricular ejection fraction | sinus rhythm | PERIPHERAL VASCULAR DISEASE | CANDESARTAN | THROMBOEMBOLISM | Follow-Up Studies | Humans | Middle Aged | Male | Diabetes Mellitus, Type 1 - complications | Peptide Fragments - blood | Aged, 80 and over | Adult | Female | Stroke - epidemiology | Natriuretic Peptide, Brain - blood | Benzimidazoles - therapeutic use | Heart Failure - complications | Stroke - prevention & control | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Rosuvastatin Calcium | Biomarkers - blood | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Stroke Volume | Cardiovascular Agents - therapeutic use | Stroke - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atrial Fibrillation - etiology | Fatty Acids, Omega-3 - therapeutic use | Tetrazoles - therapeutic use | Aged | Fluorobenzenes - therapeutic use | Fatty Acids | Peptide Fragments/ blood | Omega-3/ therapeutic use | Tetrazoles/therapeutic use | Sulfonamides/ therapeutic use | Kardiologi | 80 and over | Biological Markers/blood | Natriuretic Peptide | Pyrimidines/ therapeutic use | Cardiovascular Agents/therapeutic use | Stroke/epidemiology/ etiology/prevention & control | Benzimidazoles/therapeutic use | Diabetes Mellitus | Type 1/complications | Brain/ blood | Cardiac and Cardiovascular Systems | Atrial Fibrillation/etiology | Fluorobenzenes/ therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/ therapeutic use | Heart Failure/complications/ drug therapy
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 02/2013, Volume 127, Issue 5, pp. 634 - 640
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 8, pp. 709 - 718
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 7, pp. 721 - 728
BACKGROUND—The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear. We assessed... 
Anticoagulants | Aspirin | Hemorrhage | Atrial fibrillation | Outcome assessment (health care) | PREDICTING STROKE | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | METAANALYSIS | CARDIOVASCULAR EVENTS | GUIDELINES | ACUTE CORONARY SYNDROMES | ANTIPLATELET | atrial fibrillation | TASK-FORCE | WARFARIN | outcome assessment (health care) | anticoagulants | aspirin | PERIPHERAL VASCULAR DISEASE | PRIMARY PREVENTION | hemorrhage | Prospective Studies | Anticoagulants - administration & dosage | Follow-Up Studies | Ticlopidine - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Risk | Dabigatran | Hypertrophy, Left Ventricular - epidemiology | Aspirin - administration & dosage | Fibrinolytic Agents - adverse effects | Benzimidazoles - administration & dosage | Aspirin - adverse effects | Atrial Fibrillation - mortality | Registries - statistics & numerical data | Fibrinolytic Agents - therapeutic use | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Aspirin - therapeutic use | Cerebrovascular Disorders - epidemiology | Benzimidazoles - adverse effects | Platelet Aggregation Inhibitors - therapeutic use | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | beta-Alanine - adverse effects | Atrial Fibrillation - drug therapy | Comorbidity | Models, Cardiovascular | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Logistic Models | Treatment Outcome | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Drug Synergism | Aged | Fibrinolytic Agents - administration & dosage | Hemorrhage - chemically induced | Usage | Anticoagulants (Medicine) | Drug therapy | Health aspects
Journal Article
Journal Article